Effectiveness of Etoricoxib as an Additive Analgesic to Epidural Analgesia in Colon or Rectal Fast-track Surgery

Claudia Spies

Status and phase: Terminated; Phase 4

Conditions: Post-operative Pain

Treatments: Drug: Arcoxia®120 mg; Drug: P Tablet White Lichtenstein

Study type: Interventional

Funder types: Other

Identifiers

NCT01259830

Etoricoxib-fast-track

Details and patient eligibility

About

Post-operative pain after laparoscopic colon and rectal surgery in fast-track design.

A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Optimized pain relief is a core component of any fast-track regimen.

In this context epidural analgesia has become the standard of care for early postoperative pain therapy.

However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present.

The purpose of this study is to demonstrate that the administration of etoricoxib 120mg additionally to the clinical routine therapy (epidural catheter) reduces the post-operative pain level during movement after laparoscopic colon surgery in the fast-track design.

Full description

A fast-track program is an evidence-based, multimodal approach for patients undergoing surgery to reduce perioperative morbidity, hospital stay and cost and to increase patient centered well-being. Particularly in visceral surgery of the colon it is gaining widespread acceptance (Schwenk 2009). Optimized pain relief is a core component of any fast-track regimen (Kehlet and Wilmore 2008). In this context epidural analgesia has become the standard of care for early postoperative pain therapy (Hasenberg 2009), providing superior pain relief compared to parenteral opioids (Block 2001).

However, it is debated whether non-opioid analgesics should be given as adjuncts when epidural analgesia is already present. Some studies have found reduced pain using NSAID as adjunct (Scott 1994), leading to a positive recommendation in the German guidelines for postoperative pain therapy (S3-Leitlinie). However, other studies (Mogensen 1992) have not found an effect of non-opioids in addition to epidural analgesia. Further studies are also needed to assess whether nonopioid adjuncts can facilitate the change from epidural to systemic analgesia (typically on the 2nd or 3rd postoperative day) and reduce opioid consumption during the days after catheter removal.

Fast-track surgery is a multi-model process, and every step in this process needs to be fine-tuned to yield best results (Langelotz 2005). Until now studies have compared only groups with either epidural or systemic analgesia, but for optimal recovery a sequential approach with a combination of both is probably a better choice. A typical multimodal analgesia regimen after removal of an epidural at our institution consists of acetaminophen and ibuprofen. Opioids are avoided if possible, but are added if needed. An improved non-opioid analgesia regimen is a sought-after goal in this fast-track-phase. The study is controlled in terms of the type of surgery (laparoscopic colon and rectal surgery) and all factors of the multimodal analgesia treatment.

Enrollment: 81 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aged 18 or over
• written informed consent
• no inclusion in other medical studies according to the AMG (German drug law) during the study period
• realization of colon or rectal surgery in the fast track design after clinical standards including an epidural catheter

Exclusion criteria

• ASA status IV-V
• allergy against etoricoxib, other components or other NSAID
• coronary heart disease
• heart insufficiency NYHA II-IV
• cerebrovascular disease
• peripheral arterial occlusive disease
• untreated arterial hypertonus
• active peptic ulcera or active gastrointestinal bleeding
• minor to severe liver dysfunction (beginning from Child - Plugh - Classification A)
• kidney insufficiency
• inflammatory bowel disease
• pregnancy (positive hCG laboratory test) or lactation
• Women of child-bearing potential who are not using a highly effective contraception method with a pearl-index < 1 during study participation and for at least 3 consecutive months after study inclusion.
• placement in an institution on order of an official authority
• missing consent for saving and passing on pseudonymous data
• hereditary galactose-intolerance, lactase deficit, glucose-galactose-malabsorption
• no correct epidural catheter placement within 48 h after surgery

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

81 participants in 2 patient groups, including a placebo group

Arcoxia® 120 mg

Experimental group

Treatment:

Drug: Arcoxia®120 mg

Sugar pill

Placebo Comparator group

Treatment:

Drug: P Tablet White Lichtenstein